Crossject

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject ^CR	Bloomberg ALCJ FP
Supergenerics / France	Web Site \| Investors Relation

Things get going

Updates

28/09/23	Other news	H1 23: no surprises before the release of ...
27/03/23	EPS	We have updated our model after the rele...
23/03/23	Earnings	FY22: not much to learn from the release
12/01/23	Financing i...	Crossject has announced it has raised €1...
26/09/22	EPS	We have only changed our short-term est...
23/09/22	Earnings	A rather reassuring H1 22
05/09/22	EPS	We have adjusted our numbers to the cur...
05/09/22	NAV	We have adjusted our numbers to the cur...
05/09/22	DCF	We have adjusted our numbers to the cur...
25/07/22	Target	Despite the fact we have quite significant...
25/07/22	EPS	Our short-term EPS forecasts have little ...
25/07/22	NAV	We have reviewed our assumptions regar...
25/07/22	DCF	Despite the fact we have changed our mi...
22/07/22	Latest	The update of our assumptions confirms ...
20/06/22	Latest	A major breakthrough for Crossject
29/03/22	Earnings	FY21: not very meaningful, as expected
17/12/21	Financing i...	New financing
24/09/21	Earnings	H1 21: unsurprising (as usual)
31/08/21	EPS	We have fine-tuned our numbers on the b...
18/08/21	EPS	We have only integrated the detailed num...
18/06/21	Latest	Another good piece of news for the group
17/06/21	Latest	A licensing agreement for Zeneo Hydroco...
31/03/21	Earnings	FY20 unsuprising; waiting for more
15/12/20	Financing i...	A double bond issue
21/09/20	Earnings	Update on the group's business
22/05/20	EPS	No major changes to our forecasts. The o...
29/03/20	Earnings	Meaningless FY19 results and product up...
23/12/19	Financing i...	Extra-financing to increase visibility
20/11/19	Financing i...	A €2.6m non-dilutive issue
15/10/19	Latest	Cooperation agreement with the US Dep...

Key Data

Next release : 19/03/2024

	12/21A	12/22A	12/23E	12/24E	12/25E
Adjusted P/E (x)	-6.80	-8.01	-19.0	8.74	4.15
Dividend yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA(R) (x)	-12.4	-16.5	-30.7	5.70	3.16
Adjusted EPS (€)	-0.45	-0.36	-0.23	0.50	1.05
Growth in EPS (%)	n/a	n/a	n/a	n/a	111
Dividend (€)	0.00	0.00	0.00	0.00	0.00
Sales (€M)	6.77	9.72	14.0	59.0	92.9
EBIT margin (%)	0.00	0.00	0.00	78.0	100
Attributable net profit (€M)	-10.7	-11.2	-8.47	18.4	38.8
ROE (after tax) (%)	325	798	550	410	112
Gearing (%)		418		173	79.2